Improvements in hip trabecular, subcortical, and cortical density and mass in postmenopausal women with Osteoporosis treated with denosumab
| Autor: | Hoi-Shen Radcliffe, Chui Kin Yuen, Arne Hoiseth, Thomas Fuerst, Cesar Libanati, Michael A. Bolognese, Edward Franek, Harry K. Genant, Jose R. Zanchetta, Klaus Engelke, Sigtas Stonkus, Michael R. McClung |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Increased bone mineral density Histology hip Physiology Endocrinology Diabetes and Metabolism Osteoporosis Urology Placebo Antibodies Monoclonal Humanized Bone resorption Bone Density medicine Humans Quantitative computed tomography Osteoporosis Postmenopausal Postmenopausal women medicine.diagnostic_test business.industry denosumab medicine.disease osteoporosis Denosumab quantitative computed tomography Bone mineral content Female Radiology business Tomography X-Ray Computed bone mineral density bone mineral content medicine.drug |
| Popis: | In the FREEDOM study, denosumab treatment (60 mg every 6 months) decreased bone resorption, increased bone mineral density (BMD), and reduced new vertebral, nonvertebral, and hip fractures over 36 months in postmenopausal women with osteoporosis. In a subset of these women, hip quantitative computed tomography (QCT) was performed at baseline and months 12, 24, and 36. These scans were analyzed using Medical Image Analysis Framework (MIAF) software, which allowed assessment of total hip integral, trabecular, subcortical, and cortical compartments; the cortical compartment was further divided into 2 areas of interest (outer and inner cortex). This substudy reports changes in BMD and bone mineral content (BMC) from baseline and compared placebo with denosumab over 36 months of treatment (placebo N = 26; denosumab N = 36). Denosumab treatment resulted in significant improvements in total hip integral volumetric BMD (vBMD) and BMC from baseline at each time point. At month 36, the mean percentage increase from baseline in total hip integral vBMD and BMC was 6.4% and 4.8%, respectively (both p < 0.0001). These gains were accounted for by significant increases in vBMD and BMC in the trabecular, subcortical, and cortical compartments. In the placebo group, total hip integral vBMD and BMC decreased at month 36 from baseline by − 1.5% and − 2.6%, respectively (both p < 0.05). The differences between denosumab and placebo were also significant at months 12, 24, and 36 for integral, trabecular, subcortical, and cortical vBMD and BMC (all p < 0.05 to < 0.0001). While the largest percentage differences occurred in trabecular vBMD and BMC, the largest absolute differences occurred in cortical vBMD and BMC. In summary, denosumab significantly improved both vBMD and BMC from baseline and placebo, assessed by QCT MIAF, in the integral, trabecular, subcortical, and cortical hip compartments, all of which are relevant to bone strength. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|